Option chain shows key data for IN8bio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for IN8bio.

IN8bio (NASDAQ:INAB) Stock, Option Chain

IN8bio

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Wall-Street-ai7-1

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ENSC

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

INAB

JCSE

SGMO

Dow Falls Over 150 Points; General Motors Tops Q3 Views

Apple, Nio, CVS Health, Stellantis, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Movers

ADXN

ATNI

BIVI

BOOM

IRTC

KSCP

MEDP

MKTW

NTBL

SNSE

TCBP

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

movers image

ALTM

AMBO

CTCX

ICCT

LDTC

MLEC

NMHI

OTRK

PALT

PLBY

RMCO

TIGR

Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

IN8bio Inc

INABA DENKISANGYO CO LTD by Inaba Denkisangyo Co., Ltd.

Inaba Denkisangyo Co Ltd

INABA SEISAKUSHO CO LTD by INABA SEISAKUSHO CO LTD.

Inaba Seisakusho Co Ltd

Inabata & Co Ltd

Earnings

Press Releases

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Health Care

IN8bio to Present at Biotech Showcase 2025 in San Francisco

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

General

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

ABVC BioPharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

BioAtla

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

CervoMed

Cyclo Therapeutics

GlycoMimetics

HCW Biologics

HOOKIPA Pharma

Kairos Pharma

Longeveron

Leap Therapeutics

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

NKGen Biotech

Nanoviricides

NextCure

Palatin Techs

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Tenax Therapeutics

HC Wainwright & Co.

Jones Trading

Laidlaw & Co.

JonesTrading

EF Hutton

Comments

IN8bio

IN8bio (INAB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga